Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Firazyr (icatibant acetate) is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.
• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• Icatibant is used for abortive treatment of HAE attacks, with comparisons to C1-INH replacement, ecallantide, or fresh frozen plasma, though specific effectiveness metrics are not provided.
• Icatibant is effective for on-demand treatment in patients with HAEnCI, showing effectiveness in subgroups with F12 and PLG mutations, particularly in addressing tongue swelling in the PLG mutation subgroup.
• For ACEI-induced angioedema, icatibant reduced the time to complete symptom resolution compared to placebo or conventional treatments, but the difference was not statistically significant.
• Icatibant was associated with injection site reactions (RR: 1.35; 95% CI: 0.53-3.45), with no significant differences in other drug-related adverse effects between groups.
• Icatibant was used effectively for on-demand treatment in patients with HAEnCI, particularly those with F12 or PLG mutations, where it showed efficacy in treating symptoms like tongue swelling; estrogen exposure in female patients with the F12 mutation exacerbated the condition. There is no statistically significant benefit of icatibant over placebo or conventional treatments in patients with ACEI-induced angioedema, though it was well-tolerated.